BiotechTube

Mevalotin

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia

Conditions

Dyslipidemia

Trial Timeline

Aug 10, 2021 → Dec 27, 2024

NCT ID
NCT05120895

About Mevalotin

Mevalotin is a pre-clinical stage product being developed by Daiichi Sankyo for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05120895. Target conditions include Dyslipidemia.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05120895Pre-clinicalCompleted

Competing Products

20 competing products in Dyslipidemia

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
33
Pitavastatin + PravastatinEli LillyApproved
85
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
85
YH14755 + Metformin + RosuvastatinYuhanPhase 3
77
YHR1705 + YHR1706 + YHR1705+YHR1706YuhanPhase 1
33
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
23
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
33
PravastatinDaiichi SankyoPre-clinical
23
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
33
LY3885125 + PlaceboEli LillyPhase 1
33
LY3561774 + PlaceboEli LillyPhase 1
33
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
52
LY3561774 + PlaceboEli LillyPhase 2
52
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
52
EvacetrapibEli LillyPhase 1
33
PPAR alpha + placeboEli LillyPhase 2
52
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
33
ABT-335 + RosuvastatinAstraZenecaPhase 1
33
AZD6615 + PlaceboAstraZenecaPhase 1
33
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85